Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter

Executive Summary

The European Medicines Agency is important to the UK but the government cannot say it will be a non-negotiable point in future talks regarding the country’s departure from the EU.


Related Content

Brexit: EMA Has A Visit A Week From Potential Hosts
UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’
‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System
EMA Post-Brexit: 'It Can’t Stay In The UK' … Or Can It?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts